Pharmacology, Toxicology and Clinical Pharmacy
Institute for Pharmaceutical and Biomedical Science, JGU
Prof. Dr. Kristina Friedland is a professor at Johannes Gutenberg University Mainz and leads a research group at the Institute of Pharmaceutical and Biomedical Sciences. Her work focuses on neurodegeneration, aging, and Alzheimer’s disease (AD), with a particular interest in mitochondrial dysfunction, RNA-based regulation, and molecular neuropharmacology.
She has over 15 years of academic research experience and previously worked in the pharmaceutical industry, which adds practical insight into drug development and biomarker discovery. Her team is involved in both basic and translational research, with applications in clinical pharmacy.
Prof. Dr. Kristina Friedland (born April 26, 1976) studied Pharmacy at Freie Universität Berlin and received her Ph.D. in 2005 from Goethe University Frankfurt. From 2005 to 2011, she worked as a postdoctoral researcher at Goethe University Frankfurt, including a research stay at the University of Alabama at Birmingham, USA. During this time, she received, together with her mentor Prof. Dr. Walter E. Müller, the PHOENIX Pharmacy Research Award for the best publication in the field of pharmacology, as well as the AGNP Award for research in the area of neuropsychopharmacology.
In 2011, she was appointed Associate Professor of Molecular and Clinical Pharmacy at Friedrich-Alexander University Erlangen. Since 2017, she has been Associate Professor of Pharmacology and Toxicology at Johannes Gutenberg University Mainz. In 2024, she declined an offer for a professorship at Martin Luther University Halle and accepted a full professorship at Johannes Gutenberg University Mainz for Pharmacology, Toxicology, and Clinical Pharmacy.
From 2012 to 2016, Kristina Friedland served as Chairperson of the Clinical Pharmacy Section of the German Pharmaceutical Society (DPhG). Between 2011 and 2017, she was a member of the scientific advisory board of the Bavarian Academy for Clinical Pharmacy and a board member of the Lesmüller Foundation. Since 2011, she has been a member of the scientific advisory board of the Scientific Institute for Prevention in Healthcare (WIPIG). Since 2018, she has also been a member of the Expert Committee on Prescription Requirements at the Federal Institute for Drugs and Medical Devices (BfArM), Bonn.
- N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer’s disease
Jörg M, Plehn JE, Kristen M, Lander M, Walz L, Lietz C, Wijns J, Pichot F, Rojas-Charry L, Wirtz Martin KM, Ruffini N, Kreim N, Gerber S, Motorin Y, Endres K, Rossmanith W, Methner A, Helm M, Friedland K.
Mol Psychiatry. 2024 May;29(5):1427–1439.
PubMed Link - Analysis of hyperforin (St. John’s wort) action at TRPC6 channel leads to the development of a new class of antidepressant drugs
El Hamdaoui Y, Zheng F, Fritz N, Ye L, Tran MA, Schwickert K, Schirmeister T, Braeuning A, Lichtenstein D, Hellmich UA, Weikert D, Heinrich M, Treccani G, Schäfer MKE, Nowak G, Nürnberg B, Alzheimer C, Müller CP, Friedland K.
Mol Psychiatry. 2022 Dec;27(12):5070–5085.
PubMed Link - Preventive Care in Type 2 Diabetes: Results of a Randomized, Controlled Trial in Community Pharmacies
Prax K, Schmiedel K, Hepp T, Schlager H, Friedland K.
Diabetes Care. 2021 Aug;44(8):e157–e159.
PubMed Link - Olesoxime improves cerebral mitochondrial dysfunction and enhances Aβ levels in preclinical models of Alzheimer’s disease
Eckert GP, Eckert SH, Eckmann J, Hagl S, Muller WE, Friedland K.
Exp Neurol. 2020 Jul;329:113286.
PubMed Link - Acid sphingomyelinase – a regulator of canonical transient receptor potential channel 6 (TRPC6) activity
Zeitler S, Ye L, Andreyeva A, Schumacher F, Monti J, Nürnberg B, Nowak G, Kleuser B, Reichel M, Fejtová A, Kornhuber J, Rhein C, Friedland K.
J Neurochem. 2019 Sep;150(6):678–690.
PubMed Link
Full Research Profile
Please visit Prof. Dr. Kristina Friedland’s ORCID Profile for a comprehensive list of publications and ongoing research activities.
To learn more about Prof. Friedland and the Meet Female Scientists initiative, please visit her profile here.
| 2023 Dissertation, The role of TRPC6 channel in the dentate gyrus and pathophysiology of traumatic brain injury | ||
| 2023 Dissertation, Involvement of N1-Methyladenosine (m1A) in the mitochondrial ND5 mRNA and the corresponding writer enzyme TRMT10C in Alzheimer’s Disease | ||
| 2023 Dissertation, Charakterisierung eines Bindemotives selektiver TRPC6-Aktivatoren und verhaltensexperimentelle Studie an der TRPC6 defizitären Mauslinie B6;129S-Trpc6tm1Lbi/Mmjax | ||
| 2022 Master´s, The role of RQC-associated proteins in the pathology of Alzheimer’s disease | ||
| 2022 Dissertation, The role of ANG tRNA-derived fragments in aging, neurodegeneration and the pathophysiology of Alzheimer’s Disease | ||
| 2022 Dissertation, SV2A – nur ein synaptisches Vesikelprotein? Die Entschlüsselung der Interaktion von SV2A und Mitochondrien in der Pathogenese und Therapie von Morbus Alzheimer | ||
| 2021 Bachelor´s, Effekte von SARS-CoV-2 ORF9b und Nukleokapsid auf die mitochondriale Gesundheit | ||
| 2020 Dissertation, Prüfung und Bewertung des bundeseinheitlichen Medikationsplans hinsichtlich Akzeptanz, Praktikabilität und Eignung zur Optimierung der Arzneimitteltherapiesicherheit | ||
| 2020 Dissertation, Die Interaktion des Sauren Sphingomyelinase/Ceramid-Systems und TRPC6 Ionen-Kanälen in neuronalen Zellen | ||
| 2020 Dissertation, Serotonin 5-HT2A – Dopamin D2-Rezeptor-Heterodimere: Charakterisierung und funktionelle Untersuchung | ||
| 2019 Master´s, Schädigung der Mitochondrien in cerebralen murinen Endothelzellen zur Aufklärung der Pathogenese der Alzheimer-Krankheit |